Form 8-K - Current report:
SEC Accession No. 0001193125-21-269499
Filing Date
2021-09-10
Accepted
2021-09-10 08:12:01
Documents
14
Period of Report
2021-09-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d228016d8k.htm   iXBRL 8-K 24839
2 EX-99.1 d228016dex991.htm EX-99.1 20242
6 GRAPHIC g228016g09a03.jpg GRAPHIC 3112
  Complete submission text file 0001193125-21-269499.txt   182350

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scph-20210910.xsd EX-101.SCH 2918
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20210910_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20210910_pre.xml EX-101.PRE 11877
7 EXTRACTED XBRL INSTANCE DOCUMENT d228016d8k_htm.xml XML 3468
Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

IRS No.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38293 | Film No.: 211245900
SIC: 2834 Pharmaceutical Preparations